Biogen to Acquire Apellis for Up to $45 Per Share in Cash and CVR Tender Offer
BIIB sits 67% above its 52-week low of $110.035 on elevated volume (2.1× avg).
Summary
Biogen has announced a definitive agreement to acquire Apellis Pharmaceuticals through a tender offer. The deal is structured at $41.00 per share in cash, with an additional contingent value right (CVR) of up to $4.00 per share tied to future SYFOVRE sales milestones. This strategic acquisition follows a series of positive developments for Biogen, including a recent license agreement, positive Phase 2 clinical trial results, and an FDA approval for Spinraza, aligning with the company's stated focus on pipeline expansion and collaborations. The acquisition represents a material investment aimed at bolstering Biogen's product portfolio and growth prospects. Traders will closely monitor the tender offer's completion, regulatory approvals, and the market's assessment of the strategic fit and financial impact of this significant transaction.
At the time of this announcement, BIIB was trading at $183.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.9B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.